Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
China
/
Pharmaceuticals & Biotech
/
WuXi AppTec
603259
WuXi AppTec
Rising US-China Tensions And Overcapacity Will Curtail Prospects
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 17 Analysts
Published
03 Aug 25
Updated
09 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
CN¥89.70
1.7% overvalued
intrinsic discount
09 Aug
CN¥91.23
Loading
1Y
120.5%
7D
-0.7%
Author's Valuation
CN¥89.7
1.7% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
CN¥89.7
1.7% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
55b
2014
2017
2020
2023
2025
2026
2028
Revenue CN¥55.4b
Earnings CN¥13.9b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
11.32%
Life Sciences revenue growth rate
0.33%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.30%
Calculation
CN¥13.87b
Earnings '28
x
21.67x
PE Ratio '28
=
CN¥300.50b
Market Cap '28
CN¥300.50b
Market Cap '28
/
2.64b
No. shares '28
=
CN¥113.76
Share Price '28
CN¥113.76
Share Price '28
Discounted to 2025 @ 7.30% p.a.
=
CN¥92.10
Fair Value '25